Stephen J Nicholls1, Kristen J Bubb2. 1. Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. stephen.nicholls@monash.edu. 2. Biomedical Discovery Institute, Monash University, Melbourne, Australia.
Abstract
PURPOSE OF REVIEW: Despite widespread targeting of cardiovascular risk factors, many patients continue to experience clinical events. This residual risk has stimulated efforts to develop novel therapeutic approaches to target additional factors underscoring cardiovascular disease. This review aimed to summarize existing evidence supporting targeting of Lp(a) as a novel cardioprotective strategy. RECENT FINDINGS: Increasing evidence has implicated lipoprotein (a) [Lp(a)] in the pathogenesis of both atherosclerotic and calcific aortic valve disease. Therapeutic advances have produced novel agents that selectively lower Lp(a) levels, which have now progressed to evaluate their impact on cardiovascular events in large clinical outcome trials. Evidence continues to accumulate suggesting that targeting Lp(a) may be effective in reducing cardiovascular risk. With advances in Lp(a) targeted therapeutics, clinical trials now have the opportunity to determine whether this strategy will be effective for high-risk patients.
PURPOSE OF REVIEW: Despite widespread targeting of cardiovascular risk factors, many patients continue to experience clinical events. This residual risk has stimulated efforts to develop novel therapeutic approaches to target additional factors underscoring cardiovascular disease. This review aimed to summarize existing evidence supporting targeting of Lp(a) as a novel cardioprotective strategy. RECENT FINDINGS: Increasing evidence has implicated lipoprotein (a) [Lp(a)] in the pathogenesis of both atherosclerotic and calcific aortic valve disease. Therapeutic advances have produced novel agents that selectively lower Lp(a) levels, which have now progressed to evaluate their impact on cardiovascular events in large clinical outcome trials. Evidence continues to accumulate suggesting that targeting Lp(a) may be effective in reducing cardiovascular risk. With advances in Lp(a) targeted therapeutics, clinical trials now have the opportunity to determine whether this strategy will be effective for high-risk patients.
Authors: Fleur M van der Valk; Siroon Bekkering; Jeffrey Kroon; Calvin Yeang; Jan Van den Bossche; Jaap D van Buul; Amir Ravandi; Aart J Nederveen; Hein J Verberne; Corey Scipione; Max Nieuwdorp; Leo A B Joosten; Mihai G Netea; Marlys L Koschinsky; Joseph L Witztum; Sotirios Tsimikas; Niels P Riksen; Erik S G Stroes Journal: Circulation Date: 2016-08-05 Impact factor: 29.690
Authors: Amir Ravandi; Gregor Leibundgut; Ming-Yow Hung; Mitul Patel; Patrick M Hutchins; Robert C Murphy; Anand Prasad; Ehtisham Mahmud; Yury I Miller; Edward A Dennis; Joseph L Witztum; Sotirios Tsimikas Journal: J Am Coll Cardiol Date: 2014-03-05 Impact factor: 24.094
Authors: Børge G Nordestgaard; M John Chapman; Kausik Ray; Jan Borén; Felicita Andreotti; Gerald F Watts; Henry Ginsberg; Pierre Amarenco; Alberico Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen Journal: Eur Heart J Date: 2010-10-21 Impact factor: 29.983
Authors: Rutger Verbeek; S Matthijs Boekholdt; Robert M Stoekenbroek; G Kees Hovingh; Joseph L Witztum; Nicholas J Wareham; Manjinder S Sandhu; Kay-Tee Khaw; Sotirios Tsimikas Journal: J Lipid Res Date: 2016-01-31 Impact factor: 5.922
Authors: Nikolaus Buchmann; Till Ittermann; Ilja Demuth; Marcello R P Markus; Henry Völzke; Marcus Dörr; Nele Friedrich; Markus M Lerch; Raul D Santos; Sabine Schipf; Elisabeth Steinhagen-Thiessen Journal: Dtsch Arztebl Int Date: 2022-04-15 Impact factor: 8.251
Authors: Filip M Szymański; Agnieszka Mickiewicz; Grzegorz Dzida; Iwona Gorczyca-Głowacka; Dariusz Kozłowski; Krystyna Widecka; Zbigniew Krasiński; Adam Kobayashi; Dagmara Hering; Katarzyna Mizia-Stec; Jarosław D Kasprzak; Tomasz Zubilewicz; Krzysztof Narkiewicz; Marek Koziński; Anna E Płatek; Anna Ryś-Czaporowska; Beata Chełstowska; Stefan Grajek; Marcin Wełnicki; Artur Mamcarz; Marcin Barylski; Beata Wożakowska-Kapłon; Miłosz J Jaguszewski; Marcin Gruchała; Krzysztof J Filipiak Journal: Cardiol J Date: 2021-11-23 Impact factor: 2.737